Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 9/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111436 | 0.90 | BDKRB1 (0.41) | BDKRB1EPHX2TSHRNPSR1MEN1 | |
| SCHEMBL5125343 | 0.83 | BDKRB1 (0.39) | BDKRB1EPHX2TSHRNPSR1MEN1 | |
| SCHEMBL4123581 | 0.83 | NPSR1 (0.44) | BDKRB1TSHRNPSR1MEN1KMT2A | |
| SCHEMBL4119445 | 0.79 | EPHX2 (0.49) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL5132291 | 0.78 | NPSR1 (0.43) | BDKRB1TSHRNPSR1ALDH1A1 | |
| SCHEMBL5122612 | 0.76 | BDKRB1 (0.45) | BDKRB1EPHX2 | |
| SCHEMBL5128634 | 0.76 | EPHX2 (0.42) | EPHX2MEN1MAPK1KMT2A | |
| SCHEMBL5125598 | 0.76 | EPHX2 (0.49) | EPHX2TSHRNPSR1FPR2PROKR1 | |
| SCHEMBL5128387 | 0.75 | BDKRB1 (0.38) | BDKRB1TSHRMEN1MAPK1KMT2A | |
| SCHEMBL2833249 | 0.75 | TSHR (0.46) | TSHRNPSR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | BDKRB1 3589/4885EPHX2 2526/4885TDO2 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.